首页> 外文期刊>Lupus >Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine.
【24h】

Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine.

机译:泼尼松龙和口服环磷酰胺治疗,然后联合硫唑嘌呤治疗弥漫性增生性狼疮性肾炎的长期疗效。

获取原文
获取原文并翻译 | 示例
           

摘要

The short-term outcome of patients with diffuse proliferative lupus nephritis (DPLN) has improved with advances in immunosuppressive treatment. However, the impact of different immunosuppressive regimens on long-term renal function remains to be defined. This prospective cohort study examined the long-term renal function and disease relapse in adults with biopsy-proven DPLN, significant proteinuria, and hypoalbuminemia, who had been treated with sequential immunosuppression comprising prednisolone and oral cyclophosphamide as induction followed by low-dose prednisolone and azathioprine as maintenance. Sixty-six patients with 68 episodes of DPLN were included, with follow-up of 91.7 +/- 36.7 months. 82.4% achieved complete remission and 39.1% relapsed during follow-up. Patients in partial remission were at higher risk of relapse compared with those in complete remission (hazard ratio 6.2, P < 0.001). Serum creatinine remained stable over time (P = 0.931), while creatinine clearance showed a significant increase with time after treatment (P = 0.032). Three (4.4%) patients had doubling of baseline creatinine, but none reached end-stage renal failure or died. Univariate and mixed model analyses showed that the evolution of long-term renal function was significantly influenced by the chronicity score and creatinine clearance at baseline, and by the renal function at one year after treatment. These data demonstrate the efficacy of sequential immunosuppression in preserving renal function in most Chinese subjects with DPLN. The results also indicate that irreversible renal scarring (as reflected by baseline chronicity score), renal reserve (as reflected by renal function at baseline and one year), and an induction regimen that is effective in preserving the nephron mass are critical determinants of long-term renal outcome.
机译:随着免疫抑制治疗的进展,弥漫性增生性狼疮性肾炎(DPLN)患者的短期结局已有所改善。然而,不同的免疫抑制方案对长期肾功能的影响尚待确定。这项前瞻性队列研究研究了经活检证实为DPLN,明显蛋白尿和低白蛋白血症的成年人的长期肾功能和疾病复发,这些患者接受了序贯的免疫抑制治疗,包括泼尼松龙和口服环磷酰胺作为诱导剂,然后是小剂量泼尼松龙和硫唑嘌呤作为维护。包括66例DPLN发作68例,随访91.7 +/- 36.7个月。随访期间82.4%的患者完全缓解,39.1%的患者复发。与完全缓解组相比,部分缓解组的患者复发风险更高(危险比6.2,P <0.001)。血清肌酐随时间推移保持稳定(P = 0.931),而肌酐清除率随治疗时间的延长而显着增加(P = 0.032)。三名(4.4%)患者的肌酐基线值翻了一番,但均未达到终末期肾衰竭或死亡。单因素和混合模型分析表明,长期肾功能的演变受基线时的慢性评分和肌酐清除率以及治疗后一年的肾功能的影响。这些数据证明了在大多数中国DPLN受试者中,连续免疫抑制在保持肾功能方面的功效。结果还表明,不可逆转的肾脏瘢痕形成(如基线慢性病评分所反映),肾脏储备(如基线和一年中肾功能所反映)以及有效地保存肾单位量的诱导方案是长期治疗的关键因素。足月肾结局。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号